ArticleGastroenterology report2026
Synergistic effects of sacituzumab govitecan and radiotherapy in preclinical models of colorectal cancer.
Article in Gastroenterology report, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although radiotherapy (RT) remains the standard of care for locally advanced colorectal cancer (CRC), intrinsic and acquired resistance frequently compromise long-term outcomes. Sacituzumab govitecan (SG)-a TROP2-directed antibody-drug conjugate-offers a targeted platform for intracellular SN-38 delivery. The aim of the present preclinical study was to investigate whether SG enhances radiosensitivity in CRC, thereby providing a preclinical rationale for the clinical evaluation of SG-based combination strategies. Methods: We evaluated SG-RT synergy across CRC cell lines with differential TROP2 expression (SW480, DLD-1 vs SW620, HCT116). In mechanistic studies, clonogenic assays, flow cytometry, cell counting kit-8, Western blot, and comet assays were utilized to assess cell survival, apoptosis, and DNA damage. TROP2 was knocked down or overexpressed to validate its role in radiosensitization. Results: In TROP2-high CRC cell lines (SW480, DLD-1), combined SG and RT markedly inhibited proliferation, increased apoptosis, and amplified DNA double-strand breaks, as evidenced by elevated γ-H2AX expression and comet assay tail moments. Knockdown of TROP2 abrogated this synergy, whereas TROP2 overexpression restored it. In CDX and PDX models, SG combined with RT significantly suppressed tumor growth, increased cleaved CASP3 and γ-H2AX expression, and reduced Ki-67 without exacerbating systemic weight loss. Conclusion: Our findings identify SG as a potent radiosensitizer, providing a strong rationale for integrating SG into neoadjuvant RT regimens for locally advanced CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.